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EOSINOPHILS are present throughout the airway wall of
asthmatics.  The  nature  of  the  interaction  between
human  airway  smooth  muscle  cells  (ASMC)  and
eosinophils was investigated in this study. We demon-
strated, using light microscopy, that freshly isolated
eosinophils  from  healthy  donors  rapidly  attach  to
ASMC in vitro. Numbers of attached eosinophils were
highest at 2 h,  falling to 50% of  maximum by 20h.
Eosinophil attachment at 2 h was reduced to 72% of
control by anti-VCAM-1, and to 74% at 20h by anti-
ICAM-1. Pre-treatment of ASMC for 24h with TNF-a ,
10nM, significantly increased eosinophil adhesion to
149  and  157%  of  control  after  2  and  20h.  These
results provide evidence that eosinophil interactions
with  ASMC  involve  VCAM-1  and  ICAM-1  and  are
modulated by TNF-a .
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Introduction
Asthmatic  airways  are  hyperresponsive,  contain  an
increased amount of airway smooth muscle and are
infiltrated by a variety of inflammatory cells, including
eosinophils  and  T-lymphocytes.  It  is  now  widely
accepted that both the increased smooth muscle bulk
and inflammatory cell products contribute to airway
hyperresponsiveness. There is growing evidence that
inflammatory  cell  products  not  only  alter  the  con-
tractility of airway smooth muscle cells (ASMC) but
also their adhesion molecule expression, proliferation
and mediator secretion.1–4
Many  groups  have  demonstrated  that  eosinophil
numbers and levels of their secreted granule proteins,
both in airway fluid and in peripheral blood, correlate
with  asthma  severity.  Eosinophil  densities  in  the
lumen reflect those in the inner airway wall in fatal
asthma.5 Cytokines  such  as  interleukin(IL)-5,  pro-
duced mainly by T-lymphocytes, promote eosinophil
recruitment, activation and survival in airway tissues.6
Once  activated, eosinophils  are  a source  of  a  wide
range of mediators, many of which are implicated in
altering airway smooth muscle function. They release
the potent smooth muscle constrictors leukotrienes
C4, D4 and E4. The first direct link between eosino-
phils  and  the  induction  of  airway  hyperresponsive-
ness  was  established  when  we  demonstrated  that
supernatants from activated eosinophils increase the
contractile  responses  of  human  bronchial  rings  to
histamine in vitro.7 One eosinophil product known
to induce such in vitro hyperresponsiveness is PAF.8
However, eosinophils also release a variety of growth
factors  and  cytokines  known  to  modulate  other
functions  of  ASMC.  These  include  the  cytokines
tumour  necrosis  factor-a (TNF-a )  and  IL-1b ,  which
are present in increased amounts in the airway fluid
of asthmatics.
TNF-a and IL-1b have a variety of effects on ASMC.
They  modulate ASMC  proliferation9,10 and  increase
ASMC adhesion molecule expression.1 More recently
TNF-a and  IL-1b have  also  been  shown  to  induce
ASMC to release cytokines and chemokines, including
eotaxin and granulocyte-microphage colony stimulat-
ing  factor  (GM-CSF),  implicated  in  the  recruitment
and survival of eosinophils.11,12
Since  eosinophils  release  products  that  induce  a
variety of changes in airway smooth muscle and they
are found in this smooth muscle layer, the nature of
the interaction between these two cell-types needs to
be  investigated.  In  this  study  we  investigated  the
adhesion  of  human eosinophils  to  human ASMC  in
culture. The  adhesion  molecules  involved  and  the




All  cell  culture  requirements  were  obtained  from
Trace  Biosciences  (Sydney,  Australia)  except  for
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which were supplied by  Gibco BRL  (Life Technolo-
gies,  Melbourne,  Australia).  Antibodies  to  ICAM-1
(clone LB-2, Camfolio and HA58,  PharMingen Inter-
national),  VCAM-1  (E1/6,  Camfolio  and  51–10C9,
PharMingen  International)  and  irrelevant  antibodies
of  the  same  isotypes  were  supplied  by  Becton
Dickinson  (Sydney, Australia)  in  PBS  with  £   0.09%
NaN3 and were diluted just prior to use in RPMI-1640.
Recombinant human TNF-a and IL-Ib were supplied
by R&D Systems Inc (Minneapolis, MN, USA), recon-
stituted in PBS with 0.1% w /v bovine serum albumin
(BSA;  Sigma-Aldrich, Australia)  at  10 m g/ml  and  ali-
quots stored at –20°C. Recombinant human IL-5 was
obtained from PharMingen International (San Diego,
CA, USA), aliquots were stored at –70°C at 50 ng/m l in
PBS with 0.1% BSA. All three cytokines were diluted
immediately before use in RPMI-1640.
Human airway smooth muscle cell isolation
and culture
Human lung was obtained from patients undergoing
either  surgical  resection  or  lung  transplantation.
Human airway smooth muscle cells were prepared as
described  previously  by  Hawker  et  al.3 Briefly,
smooth muscle bundles (explants) were dissected out
of bronchial segments, washed thoroughly and trans-
ferred to culture flasks in DMEM supplemented with
10%  FBS,  L-glutamine  (4 mM)  and  antibiotics  (pen-
icillin  20 U/l, streptomycin  20 m g/ml and amphoter-
icin  B  2.5 m g/ml)  and  maintained  at  37°C  in  a
humidified 5% CO2 in air atmosphere. Medium was
changed every 5 days until the airway smooth muscle
cells (ASMC)  grew  to  confluence,  when  they  were
passaged using trypsin–EDTA. ASMC at passages 3–7
were used in the experiments described below.
Prior  to  commencement  of  experiments  the
medium on confluent ASMC  was changed to RPMI-
1640  supplemented with 10% (v/v) heat-inactivated
FBS, Hepes 2 mM, L-glutamine 2 mM and gentamycin
20 m g/ml (RPMI) for at least 24 h prior to harvest. The
ASMC  were  then  harvested  using  trypsin–EDTA,
washed thoroughly and plated into 4-well slide-wells
at  1.5–2.5  ´ 105 cells/well  in  0.5 ml  RPMI  and
cultured  for  2  days  prior  to  the  addition  of
eosinophils.
Eosinophil isolation
Eosinophils  were  isolated  from  60–120 ml  hepari-
nized peripheral blood collected from healthy volun-
teers  using modifications of the  methods of Hansel
and  colleagues.13 Briefly,  the  blood  was  mixed  5:1
with  6%  (w /v)  high  molecular  weight  dextran  in
normal saline and the red cells allowed to sediment
for  40 min  at  room  temperature.  The  leucocyte-
enriched  fraction  was  collected  and  underlayered
with  percoll  d 1.088 g/ml  and  spun  at  700´ g for
20 min  at  room  temperature.  Leucocytes  at  the
bottom of the gradient immediately above and in the
red cell pellet, were collected and the red cells lysed
with  5´ the  collected  cell  volume  of  lysis  buffer
(0.82% w /v NH4Cl, 0.1% w /v K2CO3, 0.1 mM EDTA)
for  15 min  at  4°C. The  remaining  leucocytes  were
washed  thoroughly,  incubated  with  magnetic
microbeads coated with antibody to CD16 for 30 min
at  6°C  and  cells  expressing  CD16  (neutrophils)
removed  using  a  MACS  cell  separator.  With  this
method eosinophils were isolated to ‡  95% purity and
with  ‡   98%  viability  as  assessed  by  Kimura  Light
staining and trypan blue exclusion, respectively. The
eosinophils were then immediately washed 2´ with
sterile RPMI and added to the ASMC in slide-wells at
1.5–2.5  ´ 105 eosinophils/well  and  co-cultured  at
37°C in a humidified 5% CO2 in air atmosphere for up
to 20 h as detailed below.
Slide-well processing and assessment of
eosinophil adhesion
At the appropriate harvest time the slide-wells were
gently rocked and  all  the culture medium  removed
from each well. The cell layer in the wells was then
gently washed 3´ with RPMI, drained, fixed in 100%
methanol and air-dried. The cells still adhering to the
bottom of the slide-well were stained with Kimura-
Light and the number of eosinophils attached to the
ASMC  layer  counted  in  20  fields of view (10  fields
across and 10 fields down) in each well using light
microscopy and 200´ magnification.
Time course
In  order  to  determine  the  temporal  pattern  of
eosinophil adhesion to ASMC, eosinophils were added
to  ASMC  in  slide-wells  and  duplicate  slide-wells
processed immediately or after 0.5, 1, 2, 4, 8, 16 and
20 h of co-culture.
Adhesion molecule identification
The  role  of  the  adhesion  molecules  ICAM-1  and
VCAM-1 on eosinophil adhesion to ASMC was deter-
mined  by  incubating ASMC  in  duplicate  slide-wells
with  antibodies  (1.0,  3.0  or  10.0 m g/ml)  to  either
ICAM-1, VCAM-1 or irrelevant antibodies of the same
isotype, for 30 min at 37°C prior to the addition of the
eosinophils. The slide-wells were then processed after
2 or 20 h of co-culture.
Effect of cytokines
IL-1b and TNF-a .
The effects of the cytokines IL-1b (0.1, 1.0 and 10 nM)
and  TNF-a (0.1,  1.0  and  10 nM),  alone  and  in
J. Margaret Hughes et al.
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examined by adding the cytokines, or their vehicle, to
duplicate slide-wells containing the ASMC 24h before
or at  the same time as the eosinophils. The eosino-
phils were co-cultured with  the ASMC, in  the  pres-
ence of the cytokines, for 2 or 20 h and then the slide-
wells were processed. As a result of these treatment
protocols the ASMC were treated with cytokine for a
total of 2 or 26 h when the eosinophils were present
for only 2 h and for 20 or 44 h when the eosinophils
were present for 20 h.
IL-5.
The effect of IL-5 on eosinophil adhesion to ASMC was
examined by adding the IL-5 (10 and 100 ng/ml), or its
vehicle,  to  duplicate  slide-wells  containing  ASMC
when the eosinophils were added. The cells were co-
cultured in the presence of the IL-5 for 2 or 20 h and
then  the  slide-wells  were  processed  as  described
earlier.
The combined effect of IL-5 and TNF-a on eosino-
phil adhesion to ASMC was also examined. ASMC in
duplicate  slide-wells  were  pre-treated  with  TNF-a
(10 nM) for 24 h prior to the addition of the eosino-
phils  and  IL-5  (10  and  100ng/ml). After  2 h  of  co-
culture in the presence of both the TNF-a and IL-5, the
slide  wells  were  processed  (ASMC  TNF-a
exposure=26 h).
Data analysis
The counts (2 counts of 10 fields each per well) of
eosinophils attached to ASMC per 10 fields of view for
the  duplicate  wells  receiving  each  treatment  were
averaged.  The  number  of  eosinophils  attached  to
ASMC were standardised in each experiment. For the
time  course  experiments  the  data  for  each  experi-
ment  were  expressed  as  a  percentage  of  the  max-
imum number of eosinophils attached to ASMC per 10
fields of view. In the remaining experiments the data
for each experiment were expressed as a percentage
of the untreated control.
For  each  series of  experiments ASMC  established
from  bronchial  tissue  obtained  from  3–9  different
patients were used together with eosinophils isolated
from  3–9  different  healthy  volunteer  donors.  The
percentage of eosinophils attached was averaged and
the  standard  error  calculated  for  each  time  point/
treatment.  Analyses  were  performed  on  this  mean
data  and  significance  (p£ 0.05)  determined  with
ANOVA and Fisher’s (PLSD) test.
Ethical approval
Lung samples were used with the informed consent
of each patient and with the approval of the relevant
Area  Health  Service  or  Hospital  Ethics  Committee.
Blood was collected from healthy volunteer donors
with  their  informed  consent.  Ethical  approval  for
these experiments was granted by the University of
Sydney Human Ethics Committee.
Results
Time course
Eosinophils  adhered  rapidly  to  ASMC,  with  max-
imum numbers being observed in most experiments
by  2 h  of  co-culture.  The  numbers  of  attached
eosinophils then declined to 49.4±8.9% of maximum
by 20 h (Fig. 1).
Adhesion molecule identification
Antibodies  to  the  adhesion  molecules  ICAM-1  and
VCAM-1 reduced eosinophil attachment to ASMC. Pre-
treatment of ASMC with anti-ICAM-1 (3 and 10 m g/ml)
for 30 min prior to and during a 20 h co-culture period
with eosinophils significantly (p<0.05, n=4) reduced
eosinophil attachment to the ASMC to 77.0±3.3% and
74.3±5.0% of the untreated control respectively (Fig.
2a), whereas anti-VCAM-1 had no effect (Fig. 2b). With
a  shorter  2 h  co-culture  period,  there  was  more
variability  in  eosinophil  attachment,  particularly  in
the presence of anti-ICAM-1 and the isotype control
antibody  (Fig.  2c).  Anti-ICAM-1  (3 m g/ml)  had  no
significant  effect but anti-VCAM-1 (3 m g/ml) did sig-
nificantly  (p<0.05,  n=4)  reduce  eosinophil  attach-
ment to ASMC (71.7±4.2% of the untreated control)
compared with the isotype control (118.6±16.6% of
the untreated control) (Fig. 2c).
Effects of cytokines
IL-1b and TNF-a .
IL-1b had a small effect on eosinophil attachment to
ASMC,  10 nM  IL-1b reduced  eosinophil  attachment
significantly  to  81.1±8.2%  of  the  untreated  control
compared  with  92.8±0.8%  in  the  vehicle  control
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FIG. 1. Eosinophil adhesion to airway smooth muscle cells
after various periods of co-culture. Values are means ± SE;
(n), number of  experiments; *, significantly different from
2h.(p<0.05, n=4) when present for the 20 h co-culture
period (20 h treatment) (Fig. 3a). All three concentra-
tions of IL-1b were without effect, compared to the
vehicle control, when added to the ASMC 24 h prior
to the addition of the eosinophils and left there for the
20 h co-culture period (44 h treatment) (Fig. 3a).
In contrast to these observations, TNF-a increased
eosinophil attachment to ASMC with either protocol
(20  or  44 h  treatment). TNF-a ,  0.1 nM  and  10 nM,
added  for  the  20 h  co-culture  period,  significantly
(p<0.05,  n=3)  increased  eosinophil  attachment  to
128.1±14.2% and 139.8±4.0% of the untreated con-
trol compared with 92.4±6.2% in the vehicle control
but  these  increases  were  not  significantly  different
(Fig. 3b). TNF-a , 1.0 and 10 nM, when added to the
ASMC 24 h prior to the 20 h co-culture period (44 h
treatment), also significantly (p<0.05, n=3) increased
eosinophil attachment in a concentration-dependent
manner (0.1 vs 1.0nM and 1.0 vs 10nM p<0.05, n=3)
to 119.6±9.1% and 156.5±5.2% of control respectively
(Fig. 3b).
TNF-a increased  eosinophil  attachment  to ASMC
when  the  co-culture  period  was  shortened  to  2 h.
TNF-a (10 nM) added 24 h before the 2h co-culture
period  was  started  (26 h  treatment),  significantly
(p<0.05,  n=4)  increased  eosinophil  attachment  to
148.9±13.2% of the untreated control, whereas IL-1b
was  without  effect  (112.3±12.2%,  n=4).  Neither
10 nM TNF-a ,  nor 10 nM  IL-1b , had  an effect when
added for the co-culture period only (117±10.9% and
91±9.7% of untreated control respectively, n=4).
IL-1b (10 nM)  did  not  modulate  the  increase  in
eosinophil attachment to ASMC induced by the 26 h
treatment  with  10 nM  TNF-a .  It  had  no  effect,
whether  added  with  the TNF-a (26 h  treatment)  or
only for the 2 h co-culture period (data not shown).
IL-5.
IL-5 did not modulate eosinophil attachment to ASMC
under  the  various  conditions  tested.  IL-5  (10  and
100 ng/ml) added at the same time as the eosinophils,
had no significant effect on eosinophil attachment to
ASMC following 20h of co-culture (101.0±17.6% and
91.9±10.6%  respectively,  n=3)  (Fig.4a).  It  was  also
without  effect  when  the  co-culture  period  was
J. Margaret Hughes et al.
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FIG. 2. Eosinophil adhesion to airway smooth muscle cells in
the presence of antibodies to the adhesion molecules: (a)
ICAM-1 (mouse IgG2b, clone LB-2), and (b) VCAM-1 (mouse
IgG1, clone E1/6) for 20h of co-culture, or (c) ICAM-1 (mouse
IgG1, cloneHA58) and VCAM-1 (mouse IgG1, clone51–10C9)
for 2h of co-culture or irrelevant antibodies with the same
isotypes.  Values are  means  ±  SE;  Con,  untreated control;
Veh, antibody vehicle control; *, significantly different from
the relevant isotype control (p<0.05, n = 4).
FIG. 3. The effect of: (a) IL-1b and (b) TNF-a on eosinophil
adhesion to  airway smooth  muscle  cells  after 20h  of  co-
culture. Values are means ± SE; Con, untreated control; Veh,
cytokine vehicle control; *, significantly different from cyto-
kine vehicle control (p<0.05, n = 4).shortened to 2 h (Fig. 4b). There was also no added
effect of IL-5 under conditions where TNF-a increased
eosinophil attachment (Fig. 4b).
Discussion
In this study we demonstrate for the first time that
human  eosinophils  can  rapidly  attach  to  human
airway  smooth  muscle  cells.  Maximum numbers  of
attached eosinophils were observed after around 2 h,
with numbers falling to half that level by 20 h of co-
culture.  Eosinophil  attachment  to ASMC  at  2 h  was
significantly reduced in the presence of an antibody
to the adhesion molecule VCAM-1, while at 20 h it was
significantly reduced in the presence of an antibody
to  ICAM-1.  The  pro-inflammatory  cytokine  TNF-a
significantly increased the number of attached eosino-
phils, whereas IL-1b and IL-5 were without effect.
Eosinophils have been shown to attach very rapidly
to endothelial cells, reaching maximum numbers after
5 min  of  co-culture.14 They  also  adhere  quickly  to
epithelial cells with co-culture periods of 30–60 min
commonly  being  used.15,16 We  hypothesized  that
eosinophils would also adhere rapidly to ASMC and
found that maximum numbers were reached in the
first  2 h  and  that  substantial  numbers  were  still
attached after 20h of co-culture. It would appear from
our observations, compared with those of Munoz and
colleagues,14 that eosinophils attach more slowly to
ASMC than they do to endothelial cells, as attached
eosinophil numbers were only around 50% of max-
imum after 30min.
We  investigated  whether  the  adhesion  molecules
ICAM-1  and  VCAM-1  were  involved  in  eosinophil
adhesion  to  ASMC  because  they  are  both  con-
stitutively expressed on ASMC and have been shown
to participate in the attachment of activated lympho-
cytes  to  ASMC.1 ICAM-1  and  VCAM-1  both  play
important roles in eosinophil adhesion to and transmi-
gration through vascular endothelium.17 Interestingly,
although ICAM-1 is expressed on epithelial cells, only
eosinophils activated with C5a, PMA or eotaxin (but
not RANTES, MIP-1a , FMLP, LTB4, or PAF – activated
cells) adhere in an ICAM-1 dependent manner.15,16,18
Our in vitro data are consistent with the hypothesis
that VCAM-1  is  important  in  the  initial  adhesion  to
ASMC,  as  antibodies  to  it  significantly  reduced  the
number of attached eosinophils at 2 h, but not at 20 h.
They  are  also  consistent  with  the  hypothesis  that
ICAM-1 is involved in prolonged eosinophil adhesion
to  ASMC,  as  an  antibody  to  ICAM-1  significantly
reduced attached eosinophil numbers after 20 h of co-
culture. However, neither of the antibodies inhibited
eosinophil  attachment  by  more than 28%,  so other
molecules must  also be involved in  both the  initial
phase and during prolonged adhesion.
Elevated levels of cytokines TNF-a and IL-1b have
been found in the airways of asthmatic subjects.19,20
Macrophages, other immune cells and epithelial cells
all  produce  TNF-a .  However,  mast  cells  not  only
synthesize TNF-a , but also store it  in  their  granules
and  so  are  able to  release  it  immediately following
exposure  to antigen.20 Interestingly,  in  the  airways,
mast cell numbers are highest in the smooth muscle
layer.21 IL-1b is  also  produced  by  a  wide  range  of
immune  and  structural  cells  but  the  main  source
following antigen exposure is the macrophage.22
The cytokines TNF-a and IL-1b have been shown to
affect  many ASMC  functions.  IL-1b potentiated  pro-
liferation of guinea-pig ASMC10 and TNF-a stimulated
human ASMC proliferation at low concentrations and
was inhibitory at higher concentrations.9 These cyto-
kines also stimulated ASMC secretion of a variety of
other cytokines and chemokines, including some like
GM-CSF , eotaxin and RANTES (regulated on activation
normal T-cells  expressed  and  secreted),11,12,23 with
direct  effects  on  eosinophil  recruitment,  activation
and  viability.17 In  addition,  Lazaar  and  colleagues1
demonstrated that TNF-a and IL-1b also increased the
cell  surface  expression  of  ICAM-1  and VCAM-1  on
human  ASMC.  Most  importantly  they  found  that
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FIG. 4. The effect of IL-5 on eosinophil adhesion to airway
smooth muscle cells: (a) after 20h of co-culture, and (b) 2h
of  co-culture  alone and in combination with 10nM TNF-a
added to the smooth muscle cells 24h previously. Values are
means±SE; Con, untreated control; *, significantly different
from untreated control (p<0.05, n = 4).activated  T-lymphocytes  could  then  attach  to  the
ASMC and induce ASMC proliferation. Thus ASMC are
influenced  by  their  inflammatory  environment  and
may contribute further to the inflammation, regulat-
ing it locally and attracting more inflammatory cells to
the muscle layer.
An additional finding of this study was that TNF-a
also increases the adhesion of human eosinophils to
human ASMC. TNF-a , 10 nM, increased the number of
eosinophils attaching during the first 2 h of co-culture
only if the ASMC  had  been treated with it  for  24 h
prior to the addition of the eosinophils, whereas with
an  extended  co-culture  period  (20 h),  it  always
increased the number of adhesive  cells  whether or
not the ASMC had been treated with it for 24 h before.
When TNF-a (0.1–10 nM) was present for the exten-
ded co-culture period (20h) only, it increased eosino-
phil adhesion period to the ASMC in a concentration-
independent  manner.  However,  when  a  24 h
pretreatment  period  with TNF-a was  also  included
(44 h treatment), eosinophil adhesion was increased
in a concentration-dependent manner. This apparent
difference  in  effects  of TNF-a may be  due  to  time-
related  responses  to  differential  recruitment  of  the
p55 and p75 TNF-a receptors on the ASMC and/or the
eosinophils  by  the  lower  concentrations  of TNF-a .
Prolonged treatment with TNF-a may increase adhe-
sive  eosinophil  numbers  by  increasing ASMC  adhe-
sion molecule expression, as already demonstrated for
lymphocyte adhesion to ASMC.1
IL-1b , on the other hand, was without significant
effect on eosinophil adhesion to the ASMC under all
conditions, except when present for just the 20h co-
culture period. In this instance only, it caused a slight
(19%)  but  significant  reduction  in  the  level  of
eosinophil adhesion. This lack of (or inhibitory) effect
of  IL-1b was  unexpected  as,  like TNF-a ,  IL-1b has
been shown to increase the expression of both VCAM-
1  and  ICAM-1  on ASMC  following  a  24h  treatment
period.1 However,  unlike TNF-a ,  IL-1b also  induces
ASMC  to  release PGE2.24,25 Therefore, it  is possible
that PGE2 released during the IL-1b treatment period,
might have altered the response(s) of either cell-type
and so negated any direct effects of IL-1b that might
otherwise have led to increased eosinophil adhesion
to the ASMC under the conditions reported here.
IL-5  was  also  without  an  effect  on  eosinophil
adhesion to the ASMC in this study. The IL-5 used was
biologically active as it increased eosinophil survival
when cultured alone for 24 h by up to 27% (data not
shown).  As  well  as  promoting  eosinophil  differ-
entiation,  growth,  migration  and  survival,  IL-5  has
been  shown  to  induce  eosinophil  morphological
changes rapidly26 and to enhance eosinophil adhesion
to immobilised ICAM-1 and VCAM-127 and to endothe-
lial  cells  in  an  integrin-dependent  (CD11/18)  man-
ner28 in vitro. Extracellular matrix proteins may also
mediate  eosinophil  adhesion  to  ASMC  as  integrins
bind to them and CD44, a molecule which binds to
the  matrix  protein  hyaluronate,  plays  an  important
role  in  lymphocyte  adhesion  to  ASMC.1 However,
despite  increasing  eosinophil  surface  expression  of
CD44 with a 24 h IL-5 treatment, Matsumoto et al. did
not observe increased eosinophil adhesion to immobi-
lised  hyaluronate  following  IL-5  treatment.29 Under
the conditions reported in this study, any IL-5 induced
changes  may  not  be  of  the  nature  required,  or
sufficient,  to  successfully  increase  eosinophil  adhe-
sion to ASMC, even when TNF-a does increase it.
Many studies have shown that eosinophil mediator
release  is  induced  and  modulated  by  interactions
between  eosinophil  adhesion  molecules  and  their
counter-ligands or extracellular matrix proteins.30 –34
Interestingly, ASMC production of some extracellular
matrix  proteins  is  increased  following  exposure  to
serum from an atopic asthmatic.35 Adherent eosino-
phils in the airway smooth muscle layer are therefore
likely  to  release  mediators.  Once  activated,  eosino-
phils may produce an  extensive  range  of  cytokines
and  growth  factors,  including  IL-1b , TNF-a ,  PDGF ,
FGF, TGF-b , that have been implicated in modulating
ASMC  proliferation3,9,10 and/or  mediator  produc-
tion.4,11,12The effect on the muscle cells of eosinophil
adhesion to them will vary, depending on the balance
of the many inflammatory mediators present and the
severity of the allergic response at the time.
TNF-a is  likely  to  be  present  before  and  after
eosinophils  reach  the  smooth  muscle  layer  of  asth-
matic  airways  and,  of  course,  is  likely  to  modulate
eosinophil behaviour, as well as that of the ASMC, and
so  regulate  their  interaction.  Studies  in  vitro have
demonstrated  that  TNF-a -treated  eosinophils  have
enhanced survival, up-regulated surface expression of
the activation marker CD69,36 increased adhesion to
immobilised ICAM-1 and VCAM-1,27 as well as degra-
nulation,  leukotriene  C4 and  superoxide  produc-
tion.26,37,38 Granule proteins cause tissue damage in
vitro and have been implicated in epithelial shedding
in vivo.17 We observed increased eosinophil adhesion
to ASMC with no sign of ASMC detachment or overt
morphological damage with eosinophil exposures to
TNF-a of 2 or 20h.
This  is  the  first  study  of  eosinophil  adhesion  to
airway  smooth  muscle  cells.  We  have  shown  that
adhesion is rapid and can be prolonged. As we found
it is partially mediated through ICAM-1 and VCAM-1, it
is likely to result in eosinophil mediator release and
altered airway smooth muscle responses. We have also
demonstrated  that  the  cytokine  TNF-a increases
eosinophil  adhesion  to  the  smooth  muscle  cells  at
concentrations that also induce airway smooth mus-
cle to secrete other pro-inflammatory cytokines and
chemokines. It is therefore possible that eosinophils
and ASMC  may regulate each other’s responses and
inflammation locally in asthmatic airways, contribut-
ing to the pathogenesis and symptoms of asthma.
J. Margaret Hughes et al.
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